BEP Targeting Strategies in Ethiopia

NCT ID: NCT06125860

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

6750 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-07

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized effectiveness study is to evaluate the different targeting strategies for the delivery of balanced energy and protein (BEP) supplements among pregnant women in Addis Ababa, Ethiopia. The main goals of the study are to: 1) determine the effectiveness of two individual-based antenatal BEP targeting strategies for preventing adverse pregnancy outcomes; 2) compare the cost-effectiveness of the universal BEP provision with two individual-based targeting strategies for preventing adverse pregnancy outcomes; and 3) generate implementation evidence regarding the feasibility and acceptability of different antenatal BEP targeting strategies. Pregnant women will be enrolled during pregnancy, assigned to different strategies of BEP supplementation, and followed from pregnancy through six weeks postpartum to evaluate the impacts of different BEP targeting strategies on pregnancy, maternal, and child outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small for Gestational Age at Delivery Gestational Weight Gain Stillbirth Preterm Birth Birth Weight Maternal Anemia in Pregnancy, Before Birth Neonatal Death Perinatal Death

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

balanced energy and protein supplementation food supplementation antenatal nutrition maternal nutrition gestational weight gain Ethiopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1 (control arm)

In Arm 1 (control arm), participants will receive the standard of antenatal care including iron and folic acid supplementation.

Group Type NO_INTERVENTION

No interventions assigned to this group

Arm 2 (Targeted BEP based on baseline nutritional status)

Group Type EXPERIMENTAL

Targeted BEP based on baseline nutritional status

Intervention Type DIETARY_SUPPLEMENT

In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.

Arm 3 (Targeted BEP by baseline nutritional status and monthly gestational weight gain monitoring)

Group Type EXPERIMENTAL

Targeted BEP based on baseline nutritional status and monthly GWG monitoring

Intervention Type DIETARY_SUPPLEMENT

In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.

Arm 4 (universal BEP)

Group Type EXPERIMENTAL

Universal BEP

Intervention Type DIETARY_SUPPLEMENT

In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Targeted BEP based on baseline nutritional status

In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.

Intervention Type DIETARY_SUPPLEMENT

Targeted BEP based on baseline nutritional status and monthly GWG monitoring

In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.

Intervention Type DIETARY_SUPPLEMENT

Universal BEP

In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. pregnant women aged 18 to 49;
2. attending antenatal visits in one of the study health facilities;
3. with a gestational age of 24 weeks or less;
4. no known allergies to peanuts or soybeans;
5. having resided in the current location for at least 6 months;
6. intending to continue antenatal follow-up in the health facility;
7. intending to give birth and remain in the study area until six weeks after delivery; and
8. willing to take the BEP supplements for the entire duration of the pregnancy if eligible.
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Addis Continental Institute of Public Health

OTHER

Sponsor Role collaborator

George Mason University

OTHER

Sponsor Role collaborator

Harvard School of Public Health (HSPH)

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wafaie Fawzi

Richard Saltonstall Professor of Population Sciences, and Professor of Nutrition, Epidemiology, and Global Health

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wafaie W Fawzi, DrPH, MBBS

Role: PRINCIPAL_INVESTIGATOR

Harvard School of Public Health (HSPH)

Yemane Berhane, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Addis Continental Institute of Public Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Addis Continental Institute of Public Health (ACIPH)

Addis Ababa, Addis Ababa, Ethiopia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ethiopia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wafaie W Fawzi, DrPH, MBBS

Role: CONTACT

Phone: 617-432-7598

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yemane Berhane, MD, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Wang D, Shifraw T, Costa JC, Abdelmenan S, Tsegaye S, Berhane Y, Gulema H, Berhane H, Fasil N, Workneh F, Tarekegn W, Wang M, Menzies NA, Worku A, Berhane Y, Fawzi WW. Targeting strategies of antenatal balanced energy and protein supplementation in Addis Ababa, Ethiopia: study protocol for a randomized effectiveness study. Trials. 2024 Apr 30;25(1):291. doi: 10.1186/s13063-024-08002-2.

Reference Type DERIVED
PMID: 38689304 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB22-1245

Identifier Type: -

Identifier Source: org_study_id